Made to Stick: Anti-Adhesion Therapy for Bacterial Infections

A major advantage in targeting adhesion is that the body clears invading pathogens instead of killing them
Anne-Marie Krachler and Kim Orth
The increasing repertoire of bacterial resistance is reducing the effectiveness of antimicrobial drugs and poses a major challenge to those seeking to identify replacements and alternatives. Some bacterial infections are now diffıcult to treat or untreatable. This diffıculty is especially challenging with chronic infections such as Pseudomonas aeruginosa in cystic fıbrosis patients and recurrent infections such as uropathogenic Escherichia coli in the urinary tract.
Instead of playing catch-up, some efforts focus on developing alternative treatments to infections. One approach calls for preventing bacteria from binding to host cells and tissues. Adhesion, which enables bacterial pathogens to withstand host mechanical and immunological clearance mechanisms, is a prerequisite for infection. A major advantage in targeting adhesion is that the body clears invading pathogens instead of killing them. Clearance avoids imposing selective pressure for survival, meaning the balance within the microbial population does not shift to favor resistant mutants, as happens when conventional antimicrobials are being used. Furthermore, harmful side effects from bacteriolysis, which liberates bacterial debris such as endotoxins, do not arise with anti-adhesion therapy.
Bacterial Attachment-a Three-Step Program
Adhesion to host cells precedes colonization and is necessary for pathogens to deploy virulence factors. For example, many gram-negative pathogens secrete toxins or inject effector proteins into host cells to exploit the machinery there.
For virulence factors to work effectively, pathogens need to associate intimately with their hosts. Host cell binding can be crudely divided into three sometimes overlapping steps (Fig. 1) . First, upon encountering host cells, bacteria are attracted by weak, nonspecifıc forces that are based on physicochemical surface properties, including hydrophobicity and charge, rather than by specifıc surface structures.
The next step entails stronger binding via specifıc but transient receptor interactions that allow the bacteria to sample the host cell surface through rolling and gliding movements. Finally, specifıc, high-affınity interactions between bacterial adhesins and host receptors reinforce these initial looser contacts, stably attaching the bacteria to host tissues. Typically, adhesin-receptor interactions involve specifıc sugar and peptide moieties and, consequently, anti-adhesive compounds are either glycans, peptides, or synthetic glyco-or peptidomimetics (Fig. 2) .
Anti-Adhesion Strategies Move towards Rational Design
The idea behind anti-adhesion therapy is not new. Some traditional antimicrobial therapies ➤ Bacterial adherence to host tissues is a universally required early step for establishing infections and, thus, targeting this process holds promise as an alternative approach to conventional antibiotics for treating bacterial infections.
➤ Because anti-adhesive compounds clear rather than kill bacteria, there is no selective pressure on the pathogen to develop resistance to this process, reducing the likelihood that a dominantly resistant population will develop.
➤ Although several compounds show promise, the wider use of anti-adhesion therapy will depend on the discovery of new anti-adhesion drug targets and on compounds with better affinity, stability, and bioavailability.
that target specifıc interactions between bacteria and host cells were developed intuitively, based on empirical evidence. For example, consuming cranberry juice is considered a remedy for urinary tract infections, many of which are due to fımbriated, uropathogenic Escherichia coli cells binding to bladder surfaces. The active compounds from cranberries are proanthocyanidins, which act by binding to bacterial surface structures, such as pili and flagella, thereby blocking bacterial surface targeting and adhesion. Thus, cranberry juice came into use as an anti-adhesive agent long before its mechanism of action was understood.
Meanwhile, the fırst deliberate attempt to interfere with bacterial adhesion goes back more than three decades. Making use of knowledge about interactions involving the bacterial lectin FimH at the pilus tip with mannosylated host cell receptors, researchers used soluble mannose derivatives to block fımbriated, uropathogenic E. coli from adhering to bladder tissue and, thus, prevent urinary tract infections in mice. However, these early attempts required high doses of those inhibitors and the competitive effect was rather weak, owing to the fact that each bacterium has many pili on its surface, each capable of binding to a host receptor-that is, the pathogen-host interactions are highly multivalent.
Better understanding the basis of bacterial adherence will improve our ability to design antiadhesive compounds. Recent insights into the structural basis of the FimH-receptor interaction make it possible to develop mannose derivatives that better complement the structure of FimH. Hence, they have as much as fıve orders of magnitude higher affınities than do earlier FimH antagonists. The new FimH inhibitors also have enhanced oral availability, better solubility, and greater metabolic stability than their predecessors. In mice, some of the newer FimH inhibitors prove as effective in preventing bacterial colonization of the urinary tract as ciprofloxacin, a fluoroquinolone antibiotic, is at combating urinary tract infections.
Structural biology generally plays an important role in the development of new anti-adhesive compounds. Structural insights into chaperoneusher pili biogenesis, for example, helped in developing compounds that inhibit pilus-mediated bacterial adherence by blocking the assembly of pilus subunits. Such "pilicides" block the chaperone-usher system responsible for exporting and assembling pilus subunits. Moreover, they target all bacteria that use pili as a means for adhering to host tissues.
Although most anti-adhesives developed so far target sugar-based interactions, peptidebased inhibitors are also under development. Streptococcus mutans, a major causative agent of dental caries, adheres to host tissues mainly via an adhesin called streptococcal antigen (SA) I/II. Biochemical analysis of SA I/II revealed the minimal binding epitope required for its interaction with host salivary receptors. Topical application of a synthetic peptide mimicking the receptor binding site of SA I/II prevents this pathogen from recolonizing the oral cavity in humans and prevents dental decay in nonhuman primates.
Although that peptide-based inhibitor targets only specifıc streptococcal species, inhibitors can also be designed to target a broader range of bacteria. For example, multivalent adhesion molecule (MAM) 7 is an adhesin found in a wide range of gram-negative bacterial species, and MAM7-based inhibitors can prevent a broad spectrum of gram-negative infections, both by enteropathogens and pathogens isolated from wounds, in tissue culture.
Improving Anti-Adhesive Compounds
Despite its many potential advantages over conventional antimicrobial therapy, anti-adhesion therapy is not yet widely used. One unmet challenge comes in trying to cope with the multifaceted mechanisms of bacterial attachment. Because cellular adhesion is so crucial for pathogen fıtness, many bacterial pathogens carry a variety of adhesive structures. Even though some of them may be expressed only at certain stages during infection or may be tissue-type specifıc, their overall redundancy poses a major problem for anyone developing anti-adhesion therapy agents. One way to meet this challenge would be to develop and use cocktails of anti-adhesive agents that target a variety of different adhesive structures, rather than to rely on a single compound with a single target. Alternatively, anti-adhesion agents could be combined with conventional antimicrobial agents.
Additional effort involves designing compounds with stronger adhesive properties. Although available inhibitors effectively prevent bacteria from colonizing host tissues, they are not strong enough to remove bacteria that are already tightly bound to host surfaces. Thus, binding of adhesion inhibitors needs to be strengthened to enable their use for treating established bacterial infections.
One way to enhance binding is by mimicking nature, where bacteria produce and display large numbers of adhesins to bind stably to host cells. These large numbers of adhesin molecules act like Velcro, greatly enhancing overall binding avidity. Thus, even if one interaction is blocked or corrupted, many others remain intact, enabling the bacteria to remain bound to host tissues.
Introducing multivalency into anti-adhesion molecules can be done in various ways-for example, by tethering the active compound onto a large scaffold. The scaffold can be a protein, synthetic polymer, or a nanoparticle. More recently, dynamic structures are being used as scaffolds, allowing the tethered ligands some freedom of movement, thus improving their ability to interact with and inhibit equally flexible surface receptors. For dynamic display, functional moieties can be embedded in lipid bilayers or liposomes, or sugar-based inhibitors can be arranged as "wheels," which are loosely threaded onto a synthetic polymer "string," allowing the functional groups to both rotate and slide along the backbone to adapt to surface receptors.
Although these approaches prove very effı-cient in blocking bacterial adhesion, the synthesis of such inhibitors is neither easy nor cheap. One approach to lowering costs is to use nonpathogenic bacteria as platforms for synthesizing and displaying receptor mimics. Such "designer microbes" can be engineered to express lipopolysaccharides containing sugars that mimic the glycosylation pattern of toxin receptors. Once so modifıed, they act as decoys that bind and neutralize pathogen-secreted toxins. Because they can be produced on a large scale by fermentation, such designer microbes appear to be a cheaper
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Conclusions
Although anti-adhesion therapy holds great promise as an alternative to using conventional antimicrobial agents, much effort is needed to move anti-adhesion approaches towards broader applicability. Gaining a detailed knowledge of the mechanisms bacteria use to attach themselves to host cells, both by characterizing novel means of adhesion as well as the structural intricacies of known interactions, will enable us to devise better inhibitors.
Current strategies target multiple steps in the adhesion process. Some compounds interfere with biosynthesis and assembly of adhesion molecules, while others competitively inhibit binding of bacterial adhesins to host receptors. Bacterial surface structures are also targets for anti-adhesion vaccines, and this strategy may prove successful in cases of low receptor redundancy or when a key adhesive structure is targeted.
New approaches to prevent adhesion are being developed. A recent proof-of-principle study demonstrated that inhibiting conformational dynamics of pili can be an effıcient means for blocking adhesion. Under normal circumstances, the pili can uncoil and recoil under the influence of fluid shear forces, enabling fımbriated bacteria to withstand fluid clearance mechanisms. Compounds blocking these structural changes, termed "coilicides," then allow bodily fluids to remove fımbriated bacteria, such as uropathogenic E. coli, from tissue surfaces.
